Anti-vascular endothelial growth factor drugs combined with laser photocoagulation maintain retinal ganglion cell integrity in patients with diabetic macular edema: study protocol for a prospective, non-randomized, controlled clinical trial

被引:1
|
作者
Li, Xiangjun [1 ]
Li, Chunyan [2 ]
Huang, Hai [2 ]
Bai, Dan [1 ]
Wang, Jingyi [1 ]
Chen, Anqi [2 ]
Gong, Yu [2 ]
Leng, Ying [1 ]
机构
[1] Beihua Univ, Affiliated Hosp, Dept Ophthalmol, Jilin, Jilin, Peoples R China
[2] Beihua Univ, Affiliated Hosp, Dept Endocrinol, Jilin, Jilin, Peoples R China
关键词
choroidal thickness; diabetic macular edema; laser photocoagulation; retinal ganglion cell-inner plexiform layer thickness; retinal ganglion cells; retinal nerve fiber layer thickness; thickness of the macular area; vascular endothelial growth factor; visual acuity; VISUAL FUNCTION; RETINOPATHY; CONBERCEPT;
D O I
10.4103/1673-5374.382104
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The integrity of retinal ganglion cells is tightly associated with diabetic macular degeneration that leads to damage and death of retinal ganglion cells, affecting vision. The major clinical treatments for diabetic macular edema are anti-vascular endothelial growth factor drugs and laser photocoagulation. However, although the macular thickness can be normalized with each of these two therapies used alone, the vision does not improve in many patients. This might result from the incomplete recovery of retinal ganglion cell injury. Therefore, a prospective, non-randomized, controlled clinical trial was designed to investigate the effect of anti-vascular endothelial growth factor drugs combined with laser photocoagulation on the integrity of retinal ganglion cells in patients with diabetic macular edema and its relationship with vision recovery. In this trial, 150 patients with diabetic macular edema will be equally divided into three groups according to therapeutic methods, followed by treatment with anti-vascular endothelial growth factor drugs, laser photocoagulation therapy, and their combination. All patients will be followed up for 12 months. The primary outcome measure is retinal ganglion cell-inner plexiform layer thickness at 12 months after treatment. The secondary outcome measures include retinal ganglion cell-inner plexiform layer thickness before and 1, 3, 6, and 9 months after treatment, retinal nerve fiber layer thickness, best-corrected visual acuity, macular area thickness, and choroidal thickness before and 1, 3, 6, 9, and 12 months after treatment. Safety measure is the incidence of adverse events at 1, 3, 6, 9, and 12 months after treatment. The study protocol hopes to validate the better efficacy and safety of the combined treatment in patients with diabetic macula compared with the other two monotherapies alone during the 12-month follow-up period. The trial is designed to focus on clarifying the time-effect relationship between imaging measures related to the integrity of retinal ganglion cells and best-corrected visual acuity. The trial protocol was approved by the Medical Ethics Committee of the Affiliated Hospital of Beihua University with approval No. (2023)(26) on April 25, 2023, and was registered with the Chinese Clinical Trial Registry (registration number: ChiCTR2300072478, June 14, 2023, protocol version: 2.0).
引用
收藏
页码:923 / 928
页数:6
相关论文
共 50 条
  • [31] Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema
    Kelkar, Aditya
    Webers, Caroll
    Shetty, Rohit
    Kelkar, Jai
    Labhsetwar, Nikhil
    Pandit, Abhishek
    Malode, Madhulika
    Tidke, Sayali
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2020, 68 (10) : 2143 - 2147
  • [32] Clinical effects of atorvastatin combined with conbercept in the treatment of patients with macular edema secondary to retinal vein occlusion and carotid plaque: study protocol for a prospective randomized controlled trial
    Yao, Bangtao
    Wang, Bei
    Yang, Jun
    Geng, Yan
    Yu, Hao
    Liu, Yuhui
    Liu, Gang
    Wang, Xiuying
    TRIALS, 2024, 25 (01)
  • [33] Longitudinal retinal ganglion cell thickness change in patients receiving intravitreal anti-vascular endothelial growth factor for neovascular age-related macular degeneration
    Ong, Eelin
    Spooner, Kimberley
    Hong, Thomas
    Chang, Andrew
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2019, 47 : 159 - 159
  • [34] ALTERATION OF TREATMENT CHOICES AND THE VISUAL PROGNOSIS FOR DIABETIC MACULAR EDEMA IN THE ERA OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR DRUGS Analysis of the STREAT-DME 2 Study
    Shimura, Masahiko
    Hirano, Takao
    Tsuiki, Eiko
    Takamura, Yoshihiro
    Morizane, Yuki
    Akiyama, Kunihiko
    Yamamoto, Kaori
    Hikichi, Taiichi
    Koto, Takashi
    Kinoshita, Takamasa
    Kusuhara, Sentaro
    Yoshida, Shigeo
    Sakamoto, Shin-ichi
    Kimura, Kazuhiro
    Sugimoto, Masahiko
    Kida, Teruyo
    Mitamura, Yoshinori
    Takatsuna, Yoko
    Washio, Noriaki
    Osaka, Rie
    Ueda, Tetsuki
    Minamoto, Akira
    Kogo, Jiro
    Okamoto, Fumiki
    Enaida, Hiroshi
    Sakanishi, Yoshihito
    Nagaoka, Taiji
    Gomi, Fumi
    Sasaki, Mariko
    Terasaki, Hiroto
    Iwase, Takeshi
    Tatsumi, Tomoaki
    Nishi, Kosuke
    Shinoda, Kei
    Ueda, Shunichiro
    Ueda-Consolvo, Tomoko
    Nakashizuka, Hiroyuki
    Murata, Toshinori
    Kitano, Shigehiko
    Sakamoto, Taiji
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2025, 45 (02): : 335 - 344
  • [35] Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial
    Scott, Ingrid U.
    VanVeldhuisen, Paul C.
    Barton, Franca
    Oden, Neal L.
    Ip, Michael S.
    Blodi, Barbara A.
    Worrall, Martin
    Fish, Gary E.
    Scott, Ingrid U.
    Ip, Michael S.
    Blodi, Barbara A.
    Bhargava, Sangeeta
    VanVeldhuisen, Paul C.
    Oden, Neal L.
    Figueroa, Maria J.
    Musch, David C.
    Bhargava, Sangeeta
    Han, Dennis P.
    Sadda, Srinivas R.
    Williams, George A.
    Wisniewski, Stephen
    Scott, Ingrid U.
    Gaston, Janelle
    VanVeldhuisen, Paul C.
    Figueroa, Maria
    Bradley, Lena
    De Stefano, Jodi
    Guan, Eileen
    Hoehn, Anne
    Irazabal, Alexa
    Lsman, Sue
    King, Jacquie
    Kondapaka, Radhika
    Kumar, Hamsa
    Lahut, Matt
    Lindblad, Robert
    Lovett, Robin
    Oden, Neal L.
    Patschak, Michael
    Rothwell, Ro Shauna
    Smith, Rosemary
    Van Dyke, Janet
    Watson, Valerie
    Yesko, Lauren
    Blodi, Barbara A.
    Domalpally, Amitha
    Reed, Susan
    Vargo, Pam
    Reed, Cynthia
    JAMA OPHTHALMOLOGY, 2019, 137 (08) : 932 - 938
  • [36] Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy The Protocol W Randomized Clinical Trial
    Maturi, Raj K.
    Glassman, Adam R.
    Josic, Kristin
    Antoszyk, Andrew N.
    Blodi, Barbara A.
    Jampol, Lee M.
    Marcus, Dennis M.
    Martin, Daniel F.
    Melia, Michele
    Salehi-Had, Hani
    Stockdale, Cynthia R.
    Punjabi, Omar S.
    Sun, Jennifer K.
    JAMA OPHTHALMOLOGY, 2021, 139 (07) : 701 - 712
  • [37] Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials
    Hu, Qiuming
    Li, Haoyu
    Xu, Wenhua
    Du, Yi
    Ma, Chao
    He, Jianfeng
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2019, 67 (11) : 1800 - 1809
  • [38] Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial (vol 137, pg 382, 2019)
    Bressler, S. B.
    Odia, I
    Maguire, M. G.
    JAMA OPHTHALMOLOGY, 2022, 140 (10) : 1030 - 1030
  • [39] ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA An Independent Analysis of Protocol i Study Data
    Dugel, Pravin U.
    Campbell, Joanna H.
    Kiss, Szilard
    Loewenstein, Anat
    Shih, Vanessa
    Xu, Xiaoshu
    Holekamp, Nancy M.
    Augustin, Albert J.
    Ho, Allen C.
    Gonzalez, Victor H.
    Whitcup, Scott M.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (01): : 88 - 97
  • [40] Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial
    Dupas, Benedicte
    Castro-Farias, Daniela
    Girmens, Jean-Francois
    Eginay, Ali
    Couturier, Aude
    Villeroy, Frederic
    Delyfer, Marie-Noelle
    Creuzot-Garcher, Catherine
    Giocanti-Auregan, Audrey
    Beral, Laurence
    Arndt, Carl
    Mesnard, Charles
    Vicaut, Eric
    Chaumet-Riffaud, Philippe
    Durand-Zaleski, Isabelle
    Paques, Michel
    TRIALS, 2024, 25 (01)